Pacira Biosciences公布了为期12个月的试点研究结果,该研究显示Iovera°在慢性下背痛的治疗中相比于射频消融具有良好的安全性及显著的疼痛改善。
Pacira Biosciences公布了为期12个月的试点研究结果,该研究显示Iovera°在慢性下背痛的治疗中相比于射频消融具有良好的安全性及显著的疼痛改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.